Citations

Showing 10 of 108094 citations.

Financial Hardship after Hematopoietic Cell Transplantation: Lack of Impact on Survival
Khera, Nandita , Albelda, Randy , Hahn, Theresa , Coronado, Diana Salas, Odejide, Oreofe O. , Soiffer, Robert J. , Abel, Gregory A.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 13, 2018 | Volume: 27 | Issue: 3 | Pages: 345-347

10.1158/1055-9965.epi-17-1040 | PMID 29440120 Get It

Abstract Background: Financial hardship is a growing challenge for patients with blood cancer who undergo hematopoietic cell transplantation (HCT), and it is associated with poor patient-reported outcomes. In contrast, little is known about the potential impact of patient-reported financial hardship on post-HCT survival. Methods: We sought to describe the association of financial hardship with survival after HCT in a prospectively assembled cohort of patients from three large transplant centers (n = 325). Results: There was no association between financial hardship measures assessed at 6 months post-HCT and 1- or 2-year survival after HCT. Conclusions: Patient-reported financial distress after HCT does not seem to adversely affect post-HCT survival. Impact: When assessing the effectiveness of interventions to ameliorate familial financial burden among HCT, the focus should be on patient-reported outcomes rather than survival. Cancer Epidemiol Biomarkers Prev; 27(3); 345–7. ©2018 AACR.
Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH
Mengoli, Maria Cecilia , Rossi, Giulio , Cavazza, Alberto , Franco, Renato , Marino, Federica Zito , Migaldi, Mario , Gnetti, Letizia , Silini, Enrico Maria , Ampollini, Luca , Tiseo, Marcello , Fournel, Ludovic , Colby, Thomas V. , Mengoli, Maria C , Lococo, Filippo , Spagnolo, Paolo , Cottin, Vincent

Mayo Clinic

American Journal of Surgical Pathology | February 13, 2018 | Volume: 42 | Issue: 5 | Pages: 646-655

10.1097/pas.0000000000001033 | PMID 29438170 Get It

The diagnostic criteria of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) are not well defined, and DIPNECH can be mistaken for carcinoids associated with neuroendocrine cell hyperplasia (NECH). In this study, we compared clinical, radiologic, histologic, immunohistochemical, and molecular features of DIPNECH and isolated carcinoids with/without NECH. The study population included 151 cases (77 female patients and 74 male patients), 19 with DIPNECH and 132 with carcinoids with/without NECH. None of the cases displayed molecular alterations or anaplastic lymphoma kinase expression. Compared with individuals with carcinoids with/without NECH, patients with DIPNECH were more likely to be female individuals ( P <0.0001), nonsmokers ( P =0.021), and symptomatic, and to have an obstructive/mixed respiratory defect, peripheral location of the lesions, and air trapping ( P <0.0001) on chest computed tomography, and constrictive bronchiolitis on histology ( P <0.0001). Among immunohistochemical markers, DIPNECH was associated with higher expression of thyroid transcription factor-1, CD10, and gastrin-releasing peptide/bombesin-like peptide ( P <0.0001). Yet, when a purely histopathologic definition of DIPNECH was applied, 40% of isolated carcinoids also met the diagnostic criteria for DIPNECH, even in the absence of symptoms and/or radiologic abnormalities. Therefore, as DIPNECH represents a distinct clinical syndrome, we suggest the term DIPNECH be limited to cases presenting with respiratory symptoms, functional and/or radiologic abnormalities, and constrictive bronchiolitis on histology.
Superficial Solitary Fibrous Tumor
Feasel, Patrick, Al‐Ibraheemi, Alyaa , Fritchie, Karen , Zreik, Riyam , Wang, Wei‐Lien , Demicco, Elizabeth G. , Saeb‐Lima, Marcela , Goldblum, John R. , McKenney, Jesse K. , Billings, Steven D. , Rubin, Brian P. , Ko, Jennifer S.

Mayo Clinic

American Journal of Surgical Pathology | February 13, 2018 | Volume: 42 | Issue: 6 | Pages: 778-785

10.1097/pas.0000000000001027 | PMID 29438169 Get It

While superficial (cutaneous/subcutaneous) solitary fibrous tumor (SFT) have been described, definitive diagnosis is difficult due to overlapping features with other tumors. We describe the largest series to date of superficial SFT. For inclusion, SFT had to arise in dermis or subcutis. Twenty-six cases were identified. Patients ranged from 16 to 80 years (mean, 47 y) with a marked female predominance (19 F; 7 M). Tumors involved the head (11), thigh (7), back (3), shoulder (2), upper arm (1), ankle (1), and great toe (1). Mean size was 2.9 cm (range, 1.0 to 7.0 cm). The majority (n=19) had typical histologic features (cellular SFT) with irregular fascicles of spindled cells, staghorn-like blood vessels, and variable amounts of collagen. Necrosis was evident in 3 cases (all <25%). Mitotic activity ranged from 0 to 10 mitotic figures/10 high-power fields (mean, 2 mitotic figures/10 high-power fields). Seventeen of the 18 were positive for STAT6, whereas 21/22 expressed CD34. All were low risk (23/23) by proposed criteria (Demicco and colleagues), including 2 cases with malignant histology. Three could not be risk stratified due to lack of information on tumor size. Follow-up, available on 7 cases, showed no recurrence/metastasis (mean follow-up, 100 mo; range, 2 to 241 mo). Cutaneous SFT are more common in women and most often involve the head. They are usually low risk by proposed criteria and appear to behave in an indolent manner, though larger studies are needed to confirm this. Recognition that SFT may present as a superficial mass will avoid misclassification as other CD34-positive neoplasms that frequently arise in the skin and subcutaneous tissue.
Outcome measures in coeliac disease trials: the Tampere recommendations
Ludvigsson, Jonas F. , Ciacci, Carolina , Green, Peter H.R., Kaukinen, Katri , Korponay‐Szabó, Ilma R. , Kurppa, Kalle , Lundin, Knut Erik Aslaksen, Mäki, Markku , Popp, Alina , Reilly, Norelle R., Rodríguez‐Herrera, Alfonso , Sanders, David S. , Schuppan, Detlef, Sleet, Sarah, Voorhees, Kristin, Walker, Marjorie M. , Leffler, Daniel A. , Ciacci, Carolina , Green, Peter H.R. , Murray, Joseph A. , Taavela, Juha

Mayo Clinic

Gut | February 13, 2018 | Volume: 67 | Issue: 8 | Pages: 1410-1424

10.1136/gutjnl-2017-314853 | PMID 29440464 Get It

Objective A gluten-free diet is the only treatment option of coeliac disease, but recently an increasing number of trials have begun to explore alternative treatment strategies. We aimed to review the literature on coeliac disease therapeutic trials and issue recommendations for outcome measures. Design Based on a literature review of 10 062 references, we (17 researchers and 2 patient representatives from 10 countries) reviewed the use and suitability of both clinical and non-clinical outcome measures. We then made expert-based recommendations for use of these outcomes in coeliac disease trials and identified areas where research is needed. Results We comment on the use of histology, serology, clinical outcome assessment (including patient-reported outcomes), quality of life and immunological tools including gluten immunogenic peptides for trials in coeliac disease. Conclusion Careful evaluation and reporting of outcome measures will increase transparency and comparability of coeliac disease therapeutic trials, and will benefit patients, healthcare and the pharmaceutical industry.
Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States
Lazarus, Howard M. , Riehle, Ellen, Montejano, Leslie , Lenhart, Gregory, White, Robert J. , Burger, Charles D. , Ozbay, A. Burak

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | February 13, 2018 | Volume: 24 | Issue: 8 | Pages: 834-842

10.18553/jmcp.2018.17391 | PMID 29436260 Get It

Bronchobiliary fistula after multiple transcatheter arterial chemoembolizations for hepatocellular carcinoma: A case report
Wang, Caoye, Yang, Zhengqiang , Xia, Jin‐Guo, Wang, Weiping , Chen, Wenhua , Wang, Qi

Mayo Clinic

Molecular and Clinical Oncology | February 13, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3892/mco.2018.1574 | PMID 29541470 Get It

Pharmacoproteomics Profile in Response to Acamprosate Treatment of an Alcoholism Animal Model
Germany, Caroline E., Reker, Ashlie N., Hinton, David J., Oliveros, Alfredo , Shen, Xinggui , Andres‐Beck, Lindsey G., Wininger, Katheryn M. , Cvek, Urška , Nam, Hyung Wook , Nam, Hyung W , Trutschl, Marjan , Choi, Doo‐Sup

Mayo Clinic

PROTEOMICS | February 13, 2018 | Volume: 18 | Issue: 7 | Pages: No page available

10.1002/pmic.201700417 | PMID 29437267 Get It

AbstractAcamprosate is an FDA‐approved medication for the treatment of alcoholism that is unfortunately only effective in certain patients. Although acamprosate is known to stabilize the hyper‐glutamatergic state in alcoholism, pharmacological mechanisms of action in brain tissue remains unknown. To investigate the mechanism of acamprosate efficacy, the authors employ a pharmacoproteomics approach using an animal model of alcoholism, type 1 equilibrative nucleoside transporter (ENT1) null mice. The results demonstrate that acamprosate treatment significantly decreased both ethanol drinking and preference in ENT1 null mice compared to that of wild‐type mice. Then, to elucidate acamprosate efficacy mechanism in ENT1 null mice, the authors utilize label‐free quantification proteomics comparing both genotype and acamprosate treatment effects in the nucleus accumbens (NAc). A total of 1040 protein expression changes are identified in the NAc among 3634 total proteins detected. The proteomics and Western blot result demonstrate that acamprosate treatment decreased EAAT expression implicating stabilization of the hyper‐glutamatergic condition in ENT1 null mice. Pathway analysis suggests that acamprosate treatment in ENT1 null mice seems to rescue glutamate toxicity through restoring of RTN4 and NF‐κB medicated neuroimmune signaling compared to wild‐type mice. Overall, pharmacoproteomics approaches suggest that neuroimmune restoration is a potential efficacy mechanism in the acamprosate treatment of certain sub‐populations of alcohol dependent subjects.
Measuring cognition and function in the preclinical stage of Alzheimer's disease
Weıntraub, Sandra , Farias, Sarah Tomaszewski , Goldberg, Terry E. , Hendrix, James A. , Jaeger, Judith , Park, Denise C. , Ropacki, Michael T., Sikkes, Sietske A.M. , Bain, Lisa J. , Brashear, Robert, Budur, Kumar, Graf, Ana, Martényi, Ferenc, Storck, Marta Segardahl, Randolph, Christopher , Carrillo, María C. , Knopman, David S. , Langbaum, Jessica B. S. , Welsh-Bohmer, Kathleen Anne

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | February 13, 2018 | Volume: 4 | Issue: 1 | Pages: 64-75

10.1016/j.trci.2018.01.003 | PMID 29955653 Get It

Abstract The Alzheimer's Association's Research Roundtable met in November 2016 to explore how best to measure changes in cognition and function in the preclinical stage of Alzheimer's disease. This review will cover the tools and instruments currently available to identify populations for prevention trials, and measure subtle disease progression in the earliest stages of Alzheimer's disease, and will include discussions of suitable cognitive, behavioral, functional, composite, and biological endpoints for prevention trials. Current prevention trials are reviewed including TOMMOROW, Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Trial, the Alzheimer's Prevention Initiative Generation Study, and the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's to compare current approaches and tools that are being developed.
Cross‐cultural communication in pediatric oncology: Catch them when they're young
Warad, Deepti , Rodriguez, Vilmarie , Rao, Amulya Nageswara, Nageswara Rao, Amulya, Warad, Deepti M , Rao, Amulya A. Nageswara

Mayo Clinic

Cancer | February 13, 2018 | Volume: 124 | Issue: 7 | Pages: 1516-1517

10.1002/cncr.31283 | PMID 29437222 Get It